Skip to content
Search

Latest Stories

Pharmacist Support appoints five new trustees

Independent charity group, Pharmacist Support has appointed five new trustees to its board - David Downham, Karen Harrowing, Mohammed Hussain, Mala Khiroya, and Alison Scowcroft, for a term of three years.

The new recruits will join the existing Board members Anita Cawley, Catherine Harper, Paul Johnson, Steve Lutener, Esther Sadler-Williams, Mark Sweeney and Sarah Willis.


Harrowing, Downham and Hussain have begun their 3-year term in January 2022, while Scowcroft and Khiroya would join the board in June.

The new appointments are in line with the Charity’s plans, announced last year, to enhance its volunteer schemes.

“Since the launch of the charity’s new strategy in January 2020, the profession has been faced with many new challenges. We are really proud of the work we have done in the last few years to address some of these challenges,” said Pharmacist Support chief executive Danielle Hunt.

Key initiatives led by the group include launch of new counselling offer and Wellbeing Learning Platform, expansion of ACTNow wellbeing campaign and development of a new website.

Hunt added: “We still have lots of work to do, especially with the continued high levels of stress and potential burnout present within pharmacy. We are really pleased that the five new trustees bring with them a plethora of experience and skills that will further support us in the next phase of our journey.”

Who are the new trustees

David Downham: A graduate of Cambridge University, Downham qualified as a chartered accountant in the Business Assurance division of Coopers & Lybrand. He worked as head of finance for a small chain of community pharmacies in Yorkshire, from which his own business ET Downham was spun out.

Karen Harrowing: Having a rich experience of 4o years in public, private and voluntary healthcare settings, her portfolio includes independent advisory roles on regulation, quality governance and safety, an associate and partner role at the GPhC, honorary member of APTUK and a fellow of the RPS.

Mohammed Hussain: He has worked at senior level in a portfolio career spanning national regulation, education, national health care technology and service redesign. He is the senior clinical lead for Live Services at NHS Digital and a non- executive director at Bradford NHS Teaching Hospitals Trust and chair of the Quality Academy.

Mala Khiroya: Having worked as a pharmacist for over 15 years in various community and hospital pharmacy roles, Khiroya is currently the managing director and superintendent pharmacist of the outpatient pharmacies within Leicester Hospitals.

Alison Scowcroft: She is a community pharmacist with 20 years’ experience in front line pharmacy. She worked for Co-op and then Well pharmacy for 17 years, eventually moving into a variety of head office roles. Currently, she is serving as director of strategic programmes at the not-for-profit Greater Manchester community pharmacy provider company CHL.

The profession’s charity has also appointed Esther Sadler-Williams as its new chair, who took over the role in January 2022 from Steve Lutener. Sadler-Williams has over 35 years’ experience in a variety of pharmaceutical roles, and will be joined by Anita Cawley, who remains in the post of vice chair.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less